Roche makes takeover bid for Poseida Therapeutics Inc
Genentech, the US arm of Swiss-based Roche AG, plans to acquire its long-time partner in allogeneic CAR-T blood cancer and gene therapies, Poseida Therapeutics Inc, for up to US$1.5bn.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
EC ordered to pay cost of PharmaMar vs EMA case
The General Court of the EU orders the European Commission to pay the costs in the case of Aplidin® against the Spanish company PharmaMar SA, in which an EU marketing authorisation was not granted due to conflict-of-interests within the CHMP of the European Medicines Agency.
New method set to speed up protein design
Researcher from China, Germany and the US have developed a method for designing large new proteins with pre-defined properties in the lab using Alphafold2.
Circio Holding ASA inks collaboration agreement with Certest Biotec SL
Circio Holding ASA has inked a collaboration with Certest Biotec, SL to find and test circVec LNP-formulations to deliver its circular RNA therapeutics to target tissues for gene therapies.
Country alliance calls for EU protein strategy
A dispute is brewing in Europe over climate-friendly protein production in fermenters between EU member states that are in favour of or against protein production independent of agricultural land. Germany, Denmark and supporters called on the EU Commission to formulate a European protein strategy triggering protests from farmers.
ATB Therapeutics raises €54m in Series A financing
Belgian ADC specialist ATB Therapeutics BV has kicked off with €54m from EQT Life Sciences and MRL Ventures Fun to push its payload technology towards clinical development.
Tetraspecific B/NK cell better than T cell engagers
Innate Pharma SA has presented promising preclinical data of its tetraspecific antibody-based B and NK cell engager IPH6501, a novel approach to treat B cell non-Hodgkin lymphoma (B-NHL).
Adaptimmune nears second approval for TCR-T therapy
After meeting the primary endpoints of a pivotal Phase II trial, UK-based Adaptimmune Ltd. is submitting an FDA Biologics License Application for its autologous T-cell receptor therapy (TCR-T) Lete-cel (letetresgene autoleucel).
Pharmahungary Group participates in ambitious EU EVEREST Project
Pharmahungary Group has announced it will be participating in a project aiming to set up standardised methods to examine intercellular and interorgan communication via extracellular vesicles, the next Big thing in the diagnosis and therapy of cancer and cardiovascular diseases
Alentis Therapeutics raises US$181.4m in Series D financing
Swiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours.